<DOC>
	<DOCNO>NCT01586936</DOCNO>
	<brief_summary>This study conduct Japan . The aim registry study observe use single dose multi-dose use eptacog alpha ( NovoSeven® ) compare short-term outcome , include effectiveness , safety , quality life treatment satisfaction approve treatment .</brief_summary>
	<brief_title>Non-Interventional Study NovoSeven® Used On-demand Treatment Bleeds Patients With Haemophilia A B With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Treated eptacog alpha ( NovoSeven® ) Investigator decision measure antibody unnecessary medical testing</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>